Eyeworld Daily News

20 | EYEWORLD DAILY NEWS | APRIL 5, 2024 ASCRS ANNUAL MEETING DAILY NEWS intended to provide visual benefits before light treatments begin and extends depth of focus relative to the original LAL. Dr. Schallhorn shared that get- ting the Light Delivery Device and postop adjustment process for the LAL took time for her practice. She asked Dr. Kurtz how RxSight plans to help physicians incorporate the newer lens into their practice. Dr. Kurtz said that the LAL+ uses the same process as the original LAL, but encouraging greater market adoption starts with delivering the best clinical outcomes. After that, he said, it takes commitment. "When you're changing a par- adigm, it takes a commitment not only on the industry part but also the clinical side," he said. RxSight is taking learnings from early adopters and creating a process that is then disseminated to new users. Editors' note: The speakers have fi- nancial interests with their associated company. VISUMAX 800 (Carl Zeiss Meditec) Dirk Muehlhoff, with Carl Zeiss Meditec, and Andy Chang, with Carl Zeiss Meditec, spoke about this tech- nology, which received FDA approval in January. Mr. Chang said that the technology incorporates feedback from experience with the original VISUMAX platform to deliver the SMILE procedure. Some of the new features include a reduced speed for lenticule creation (10 seconds), tech- nical abilities to correct centration and alignment, and a comfortable surgical experience. The laser treatment time being reduced matters, Mr. Muehlhoff said. "This is the time when everyone is holding their breath—surgeon and patient included," he said. Less time equates to less anxiety and fewer problems, Mr. Muehlhoff said. Mr. Chang said the VISUMAX 800 will be a benefit in Asia where the SMILE market is maturing, but it also provides the opportunity in the U.S. and other parts of the Western world to "go back in and showcase what we can do with the latest generation 2 device." Mr. Muehlhoff added later that physician users are saying that patient perception of SMILE with the VISUMAX 800 is as good if not better than LASIK and carries less fear of flap complications and attraction as a more minimally invasive procedure. LAL+ (RxSight) This lens is launching at the 2024 ASCRS Annual Meeting, building upon the original Light Adjustable Lens (LAL) platform. The LAL+ adds a small continuous increase in central lens power molded into the anterior surface of the lens. This, Ron Kurtz, MD, with RxSight, said is " W heels Up: New Products Attempt- ing to Takeoff" featured discussions on new product launches—early experiences and what the companies are doing to facilitate success. XDEMVY (lotilaner ophthalmic solution, 0.25%, Tarsus Pharmaceuticals) Aziz Mottiwala, with Tarsus Phar- maceuticals, and Elizabeth Yeu, MD, spoke about this product's launch, which began in August 2023. Mr. Mottiwala credited XDEMVY's suc- cess so far to a great team, market education efforts, and the value proposition with payers. He said more than 17,000 patients were served in the first quarter, and more than 6,000 eyecare professionals wrote prescriptions for XDEMVY. "The most exciting thing is the feedback we're getting from phy- sicians and patients. The drug has performed extremely well … as well, if not better, than the clinical stud- ies," he said. Moderator Julie Schallhorn, MD, asked Mr. Mottiwala about education on which patients will benefit from XDEMVY. Mr. Mottiwala said this has been thoughtful and methodical with the recommendation being to target patients with clear collarettes, red- ness, and at least one complaint first. He said once physicians have 5–10 of these "traditional" blepharitis pa- tients treated with XDEMVY, they're starting to take a look at other types of patients who might benefit, such as those with recalcitrant dry eye that is not addressed with current medications. 'Wheels Up': New product launches Mr. Chang speaks about the launch of the VISUMAX 800 laser and how it will allow representatives in the U.S. market to "showcase what we can do with the latest generation 2 device." Source: ASCRS

• Cover